kff 2025 employer health benefits survey glp-1 coverage In 2025: Family Premiums Rise 6 Percent, Large Employers Increase Of GLP-1s For Weight Loss Annual Family Premiums for Employer

As with all investigational medicines, the safety profiles of cagrilintide and retatrutide are still being characterised through ongoing clinical trials

Be mindful that regardless of your choice, behavior is usually a key ingredient for successful weight management

Tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, reports injection site reaction rates of approximately 1.7-2.2% in its FDA prescribing information, similar to semaglutide

To truly understand this, theres a common question we need to consider: Can semaglutide cause muscle cramps

Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, et al